Thirty-three patients with acute nonlymphocytic leukemia were studied during remission-induction treatment in a double-blind, placebo-controlled, randomized study to ascertain the effect on the incidence of infection of an oral regimen of selective antimi crobial modulation (SAM). A decrease in the number of major acquired infections was observed: three infections occurred in 16 patients receiving the SAM regimen compared with eight infections in 17 patients given the placebo. The reduction of infection was correlated with a reduction of fever, with a reduction of the frequency of administra tion of antimicrobial agents for the treatment of infection, and with the selective elimi nation of aerobic and facultative anaerobic gram-negative rods from the digestive tract. Substantial unfavorable side effects were not observed.
Patients with acute leukemia experience prolonged periods of neutropenia due to their disease or its treatment. For this reason they often develop seri ous infectious complications. Although antibiotic therapy has improved in recent years and the fatal ity rate has been decreased, infection is still an im portant cause of morbidity and mortality in pa tients treated for acute leukemia [1] . Prevention of infections by protective isolation and supression of intestinal flora probably reduces a part of the infectious problems.
Since 1976, infection prevention in the isolation ward of our hospital has consisted of protective isolation (laminar airflow rooms and food with a low bacterial level) and selective elimination of po tentially pathogenic aerobic and facultative an aerobic bacteria from the skin and mucosal sur faces [2] . The combination of antimicrobial agents chosen for administration to the patients at risk has only limited or no activity against anaerobic bacteria [3] . The objective goal of this regimen of Received for publication July 30, 1982, and in revised form November 29, 1982.
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Please address requests for reprints to Dr. R. van Furth, De partment of Infectious Diseases, University Hospital, Rijnsburgerweg 10, 2333 AA Leiden, the Netherlands. selective antimicrobial modulation (SAM) [3] (re ferred to as partial antibiotic decontamination elsewhere [2] ) is to preserve colonization resistance [3, 4] . Colonization resistance refers to the resis tance that microorganisms must overcome before they can colonize body surfaces [5] . The SAM ap proach seemed justified because aerobic bacteria are frequently involved in infectious complica tions in neutropenic patients, whereas the an aerobic bacteria seem to be relatively harmless [6] .
From a previous study it was concluded that the SAM regimen prevents major infections in pa tients with severe bone-marrow failure [3] , but it remained uncertain whether the SAM regimen would have the same favorable effect in hospitals with restricted facilities for protective isolation and bacteriologic control. The present study was performed to determine whether selective elimina tion of aerobic and facultative anaerobic gramnegative bacteria from the intestinal tract would reduce the number of infectious complications without the use of other sophisticated preventive measures.
In contrast to the previous study [3] , no local antimicrobial treatment was applied to the oral cavity and skin, the patients were not isolated in laminar airflow rooms but were nursed in single bed rooms, and patients were given conventional hospital food with some restriction of heavily con taminated food. Moreover, the attending physi cians were not told the results of surveillance cul tures of the patients. The present report describes the results of this double-blind, placebo-controlled study on the ef ficacy of the SAM regimen in patients with acute nonlymphocytic leukemia who were nursed in conventional single-bed rooms.
Patients and Methods
Patient selection and randomization. All adult patients admitted between September 1977 and October 1981 with acute nonlymphocytic leu kemia, and for whom a single-bed room was avail able, were eligible for the study. After informed consent was obtained, the patients were randomly assigned to receive the SAM regimen or placebo. Infection, fever, or other clinical complications present at the time of randomization did not ex clude the patients from the study.
After randomization the patients were subjected to conventional physical and base-line bactério logie examination. Simultaneously, or within a few days after the initial administration of the SAM regimen or placebo, therapy for leukemia was begun. Only patients who had received the SAM regimen for at least one week and patients with granulocytopenia (granulocyte count, <500/ mm3) for at least one week were evaluated.
Infection prevention. Patients receiving SAM or placebo were nursed in conventional single-bed rooms. Persons entering a patient's room were re quired to wash their hands with povidone-iodine soap and to wear a mask and a gown that was only used in that room and that was replaced with a clean one at least once a day. The patients were not permitted to leave the room, except for exam ination elsewhere in the hospital or for a few days' stay at home (at most, for seven days) between two courses of cytostatic therapy. During the lat ter period the SAM regimen or placebo was con tinued at home. Both patient groups were given conventional hospital food with some restrictions concerning food assumed to be heavily contam inated (for example, raw meat and fish and deepfried food from snack bars).
The SAM regimen consisted of four capsules (size, 6x18 mm) containing a mixture of neomy cin, polymyxin B, and amphotericin B, given four times daily, and two capsules (size, 8 x 24 mm) containing nalidixic acid, given twice daily. The total dosage of these prophylactic antimicrobial drugs administered daily was 1 g of neomycin, 1 g of amphotericin B, 2 g of nalidixic acid (in the pre vious study [3] , 4 g was given), and 400 mg of polymyxin B. The placebo consisted of capsules containing starch that were matched for size and color. All patients were treated locally in the nose with a cream containing 0.5970 neomycin and 0 . 1 % chlorhexidine hydrochloride to prevent carriage of Staphylococcus aureus. No other topical anti septics were used.
The patients started their prophylactic regimen as soon as the base-line bacteriologie cultures had been obtained. If the clinical condition deteri orated because of the disease or antileukemic treatment, the patients were stimulated to swallow all of the capsules. When this was not possible, they were allowed to use fewer capsules during periods of chemotherapy. The capsules were swal lowed whole, or they were opened and the con tents were suspended in tea or another drink, which the patients drank during or after meals.
Prophylaxis or placebo was terminated and no further cytostatic therapy was given as soon as granulocyte counts exceeded 500/mm3 or if the at tending physicians judged continuation of pro phylaxis or placebo to be useless for clinical or psychological reasons.
Bacteriologie investigations. Bacteriologie sur veillance cultures were obtained once a week and included cultures of urine, feces, and swabs taken from the nasopharyngeal, oropharyngeal, geni tourinary, and perineal regions. The semiquantitative and qualitative bacteriologie techniques have been previously described [2] . The results of these surveillance cultures were not provided to the at tending clinical staff. Bacteriologie examination for diagnostic purposes was performed when the clinical condition suggested bacterial infection.
M anagement o f infection. In all patients, sys temic antibiotic treatment was not instituted until infection was seriously suspected or proven. The choice of antibiotics was governed by the site of the infection and the suspected causative micro organisms. If the causative infectious agents were unknown, therapy almost always consisted of combinations of two antibiotics given iv. When ever possible, antibiotic therapy was adjusted on the basis of the results of bacteriologie investiga tion.
D efinition o f infections. Infections were di vided into bacterial, fungal, viral, and protozoan infections. The bacterial and fungal infections, whether microbiologically proven or not, were di vided into minor infections (clinically manifested infections of the skin or mucosa without extension to deep tissue, such as stomatitis, gingivitis, or pharyngitis) and major infections (infections with extension to the blood, deep tissues, or organs, such as pneumonia or pyelonephritis). Infections were called doubtful if the diagnostic procedures did not give conclusive results and the patient's clinical condition (fever) was the only suggestion of infection and if no response to antimicrobial therapy was observed.
Acquired infections were defined as infections showing their first clinical signs after the first week of the SAM regimen or placebo.
Fever. Each day on which a patient's axillary body temperature at least once was ^38 C was de fined as a day with fever. An axillary body tem perature of >39 C was considered to be high fever.
Granulocytopenic episodes. A period of two or more successive days with granulocyte counts of <500/m m 3 was defined as a granulocytopenic period.
Therapy fo r hematologic disease. All patients were treated with one or two remission-induction regimens. The LAM V treatment protocol (no. 06781) of the European Organization for Research on Treatment of Cancer (Zurich) consists of 1 mg of vincristine/m2 of body surface area on day 1, 50 mg of doxorubicin/m2 on day 2, and 80 mg of cytarabine/m2 twice daily on days 3-9. The COAP protocol, which is less cardiotoxic, consists of 1.4 mg of vincristine/m2 on day 1, 100 mg each of cyclophosphamide and cytarabine/m2 on days 1-5, and 40 mg of prednisone/m2 on days 1-5. In the present study, all patients received the LAM V treatment protocol except two, one in each group, who received the COAP protocol because of their advanced age.
Questionnaires. The patients were given a multiple-choice questionnaire after receiving the SAM regimen or placebo for three or more weeks. The questions concerned appetite and nausea.
Statistical evaluation. Statistical evaluation of differences was determined by Wilcoxon's twosample test.
Results
Comparability o f the randomized groups. For ty-two patients were randomized; 2 1 patients were allocated to receive the prophylactic regimen (SAM), and the other 21 patients received place bo. Five patients in the SAM group were excluded from the study because the period during which they received the SAM regimen or the period dur ing which they were at risk was too short for eval uation (one week or less). In these patients pro phylaxis was terminated on psychological grounds in one patient, because of a clinical condition too poor to permit cooperation in two patients, and because the granulocytopenic period was too short (fewer than seven days with granulocyte counts of <500/m m 3) in the other two patients. In the con trol group four patients were excluded: one be cause of psychological reasons, one because the code was broken as the result of hearing loss (which was suspected to be due to neomycin), one because his poor clinical condition made it impos sible for him to swallow the placebo for at least one week, and one because the granulocytopenic period lasted for fewer than seven days. The re maining patients, 16 in the SAM group and 17 in the placebo group, were comparable as to age, di agnosis, antileukemic therapy (table 1 ), and clin ical condition at the time of randomization (table  2) . No significant differences in the response to hematologic treatment and the number of granu locytopenic days, platelet transfusions, and days of the SAM regimen or placebo were observed be tween the two groups (table 2) . Efficacy o f antimicrobial prophylaxis. Infec tion. It was assumed that the SAM regimen takes at least one week to become effective for the prevention of infection. Therefore, the first week of prophylaxis has been evaluated separately from the remaining period of the SAM regimen. In the first week, five of 16 SAM patients became in fected or were already infected, and two SAM pa tients had fevers with unknown origins (table 3) . One of these infections was a rectal abscess that, after drainage, was found to be caused by Esche richia coli and Enterobacter cloacae. The other in fections were minor local infections in the oropha ryngeal region. Seven of the 17 patients who re ceived placebo became infected or were infected in the first week. One of these patients had septi- cemia due to E. coli, one had a rectal infiltrate, and one patient had a diverticulitis. The others had minor local infections in the oropharyngeal region (gingivitis, stomatitis, and pharyngitis).
The differences concerning infectious complica tions between the two groups of patients during the first week are not significant (P = 0.95). Although no differences were shown in the first week of prophylactic treatment, a decrease (P = 0.05) in the number of acquired major infections was observed in the SAM patients during the re maining period compared to the patients receiving placebo (table 4) . Two of the three major infec tions acquired by the SAM patients were caused by microorganisms that are intrinsically insensi tive to the SAM regimen -septicemia due to Streptococcus pneum oniae and a rectal infiltrate probably caused by anaerobic bacteria and Strep tococcus faecalis. In the third patient, septicemia with E. cloacae occurred. This infection was con sidered to be of exogenous origin -a secondarily infected herpes labialis lesion. Among the controls there were seven cases of septicemia due to gramnegative organisms, most of which probably orig inated from the oropharyngeal or rectal regions; one of these patients also developed pneumonia caused by Legionella pneumophila.
No differences were found between the SAM group and the placebo group with respect to local and doubtful infection. Evidence of viral infection was obtained in two SAM patients; those infec tions were due to herpes simplex virus, one of which was associated with a secondary bacterial infection as mentioned above. In the patients given placebo, lesions due to herpes simplex virus became secondarily infected with Klebsiella pneu moniae.
A ntibiotic use. The reduction of infectious complications in the SAM group was associated with a reduction of the use of both aminoglyco sides and cephalosporins; the use of penicillin, trimethoprim-sulfamethoxazole, and other antibi otics was not lower than that in the placebo group (table 5) . Aminoglycosides were administered for the treatment of an assumed infection in six SAM patients, and retrospective analysis reveals that this had not been necessary in at least four of them.
Fever. Although the reduction of the inci dence of major infection in the SAM group in comparison to the placebo group is obvious, the effect on fever is less pronounced. In the SAM group, fever occurred on a mean of 9.5 days (19%) during the mean prophylaxis period of ~50 days, whereas fever occurred on 14 days (31%) during the mean prophylaxis period of 45 days for the patients given the placebo. To find out whether this difference was associated with a reduced incidence of infection, only days with fever during the risk period (granulocyte counts, <500/m m 3) were considered for statistical evalua tion. Single days during which a patient's fever was probably not associated with infection (total, nine days for the SAM group and 26 days for the placebo group) and days with fever occurring after the termination of prophylaxis or placebo were not included.
In the SAM group, 22 granulocytopenic epi sodes occurred, of which eight were not associated with fever; in the control group, 20 granulocy topenic episodes occurred, of which seven were not associated with fever. The mean duration of the granulocytopenic episodes without fever was about 18 days for both groups. The duration of the other granulocytopenic episodes -those that were associated with fever -was longer, amount ing to a mean of 28 and 26 days for the SAM and placebo groups, respectively (figure 1). In the SAM group, fever occurred during about 11 (41%) of these days, as compared with 13.5 (52%) days for the control group. If only days with high fever (axillary temperature, >39 C) are taken into account, the difference in the mean number of days with fever (four and 6.5 days for the SAM and control groups, respectively) is significant (P = 0.05).
Bacteriologie evaluation. The results obtained from the cultures of fecal samples obtained once 620 Guiot et al. a week are shown in figure 2 . On the first day of prophylaxis, aerobic gram-negative rods were cul tured from almost all fecal samples. After the first week the aerobic gram-negative rods had been eliminated from the stools of most SAM patients, and the fecal cultures only incidentally were found to contain aerobic gram-negative bacteria; in con trast, almost all fecal samples from the placebo group contained gram-negative bacteria. The gram-negative bacteria shown in the fecal samples of SAM patients were sensitive to the antimicro bial drugs in the SAM regimen; they were tran sient, or, if they persisted temporarily, the failure was associated with an interruption of the intake of the SAM regimen. Although the antibacterial activity of the SAM regimen was solely localized in the intestines, a reduction of aerobic gram-neg ative rods also occurred in the oral cavity and the genitourinary region and on the skin. E. coli was cultured from swabs taken from these locations ( figure 3 ) in ^2 5 % of the swabs in the SAM group and in 95% of the swabs in the placebo group. For Klebsiella species, the percentages of positive swabs were 10% in the SAM group and 20% in the placebo group, and for other Enterobacteriaceae, 5% and 40%, respectively. Pseudom onas aeru ginosa was cultured from ~1% of the swabs in the SAM group and in 15% of the swabs in the placebo group. As in the cultures of the fecal samples, these gram-negative rods were often transient in the SAM group in contrast to the placebo group. Klebsiella spp 40 -
-

Pseudomonas aeruginosa
Complications and compliance. With the ex ception of one case, none of the data indicated that either more or fewer important complications had to be attributed to the SAM regimen. This single exception concerned a patient with a hyper sensitivity reaction, probably to nalidixic acid. Comparison of the reasons for termination of the SAM regimen or placebo (table 6) reveals no dif ferences between the two groups in this respect.
Weeks on prophylaxis
Nausea occurred mainly during antileukemic treatment and was often ascribed to the intake of the capsules whether they contained the SAM regi men or placebo. Appetite was decreased similarly in the two groups, a result which is consistent with the loss of body weight because no significant dif ferences were observed between the two groups in the loss of body weight (P = 0.74). Although the patients did not report in the questionnaires that nausea was associated with the SAM regimen, their aversion to swallowing the capsules in the SAM regimen was observed by the attending staff during courses of antileukemic therapy.
Discussion
In this randomized, double-blind, placebo-con trolled study, we evaluated the efficacy of the SAM regimen on the rate of infections during remission-induction treatment in patients with acute nonlymphocytic leukemia. The SAM regimen was chosen because it selectively eliminates aerobic gram-negative bacteria from the intestinal tract and it does not affect the anaerobic flora to a mea surable degree [3] . The purpose of the preserva tion of the anaerobic intestinal flora is to retain the antagonistic activity of the anaerobes against potentially pathogenic aerobic bacteria [3, 4] . As a divergence from a previous study on SAM [3] , a number of simplifications were introduced. In the present study the patients were convention ally isolated in single-bed rooms instead of lami nar airflow rooms, conventional food was given instead of food with a low bacterial level, local an tiseptic treatment was not applied, and the attend ing physicians were not told the results of the bac-teriologic surveillance cultures. These simplifica tions were introduced to evaluate the feasibility of SAM in a conventional hospital environment.
The patients assigned to the SAM group were comparable to the patients who received placebo in every respect. A significant reduction in the number of patients with acquired major infections due to gram-negative organisms was shown in the SAM group. This reduction of infection was asso ciated with a reduction of fever and a reduction in the use of aminoglycosides and cephalosporins in the SAM group in comparison with the placebo group. However, this reduction of fever is not substantial, which suggests that many noninfectious factors are involved in the fever of patients treated for acute myelogenous leukemia. The re duction of the number of days with high fever (>39 C) in the SAM group is significant, a result which correlates with the observed reduction of major infectious complications. Almost the same results were obtained in a previous study [7] . Ob jections to the method of evaluation of the occur rence of fever, based on the possibility of bias in troduced by exclusion of fever continuing after termination of SAM or placebo, are refutable, since fever continued in one of three SAM patients and in six of seven patients who received placebo, all of whom continued to be granulocytopenic af ter termination of the SAM regimen or placebo capsules.
As a consequence of the limited isolation mea sures, contamination of the oral cavity, skin, and genitourinary region was frequently observed in the present study. The use of conventional food and the omission of topical antiseptics were prob ably responsible for these contaminations. The ex ogenous bacteria were transient in most SAM pa tients, whereas they persisted longer in the placebo group. Because of the prophylactic regimen, only a small proportion of the fecal cultures of SAM patients showed aerobic gram-negative rods com pared with those of the placebo group. It is re markable that the elimination of aerobic gramnegative rods from the intestines also resulted in a reduction of these bacteria in the oral cavity, the genitourinary region, and on the skin.
The lack of adequate isolation measures is only reflected by infection with herpes simplex virus in one SAM patient. In this patient, septicemia with E. cloacae could probably have been prevented by better isolation. Routine bacteriologic surveillance cultures in SAM patients would probably con tribute to the choice of adequate antimicrobial therapy in case of infection and to the mainte nance of the quality of prophylaxis. However, in the present study antimicrobial drugs were prob ably given more often than really needed in the SAM group because of the inaccessibility of the results of surveillance cultures.
In general, tolerance to the ingestion of the SAM regimen was reasonable. Of course, most of the patients did not like having to swallow the cap sules and tablets four times a day, but objective observations (patients' observation cards and questionnaires) did not show substantial differ ences between tolerance in the two groups. No signs of toxicity, diarrhea, or other complications attributable to the SAM regimen were observed.
It can be concluded that in general the results of the present study confirm the findings of the pre vious study on SAM [3] , indicating that major in fections with gram-negative microorganisms can be prevented by SAM. The prophylactic regimen mainly reduces morbidity; a favorable effect on remission rate and survival was not found for the small number of patients in this study.
The question of whether the SAM regimen is su perior or inferior to other regimens for selective suppression of intestinal flora cannot be an swered. The reports on the prophylactic use of trimethoprim-sulfamethoxazole, which has been claimed to be a potential method for selective sup pression of intestinal flora, suggests a favorable effect in infection prevention [8, 9] and excellent tolerance. On the other hand, prolonged granulo cytopenia [8] and selection of resistant strains have been reported [8, 10] . The chance of the se lection of resistant strains against trimethoprimsulfamethoxazole and the favorable experience with SAM have been decisive factors in our de cision to use the SAM regimen for prophylaxis in our hospital in the future and to limit the use of trimethoprim-sulfamethoxazole for the treatment of infection only.
